Fredun Pharmaceuticals Ltd

Fredun Pharmaceuticals Ltd

₹ 807 -0.82%
04 Jul - close price
About

Incorporated in 1987, Fredun Pharmaceuticals
Ltd manufactures & exports healthcare and pharmaceuticals products[1]

Key Points

Business Overview:[1]
The company, a subsidiary of the Fredun Group, manufactures pharmaceutical and allopathic formulations including tablets, syrups, capsules, and ointments across therapeutic areas like anti-diabetics, anti-retrovirals, and anti-hypertensives. It has also expanded into dietary and herbal supplements, nutraceuticals, diagnostic kits, and animal healthcare products through group entities Fredun Healthcare Pvt. Ltd. and Fredna Enterprises.

  • Market Cap 381 Cr.
  • Current Price 807
  • High / Low 904 / 635
  • Stock P/E 19.3
  • Book Value 299
  • Dividend Yield 0.09 %
  • ROCE %
  • ROE %
  • Face Value 10.0

Pros

Cons

  • Stock is trading at 2.70 times its book value

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Loading peers table ...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Mar 2025
167.41
150.16
Operating Profit 17.25
OPM % 10.30%
0.00
Interest 8.15
Depreciation 1.84
Profit before tax 7.26
Tax % 17.36%
6.00
EPS in Rs 12.71
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2025
456
401
Operating Profit 55
OPM % 12%
0
Interest 22
Depreciation 5
Profit before tax 27
Tax % 28%
20
EPS in Rs 41.81
Dividend Payout % 2%
Compounded Sales Growth
10 Years: %
5 Years: %
3 Years: %
TTM: %
Compounded Profit Growth
10 Years: %
5 Years: %
3 Years: %
TTM: %
Stock Price CAGR
10 Years: %
5 Years: 34%
3 Years: 0%
1 Year: -5%
Return on Equity
10 Years: %
5 Years: %
3 Years: %
Last Year: %

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Mar 2025
Equity Capital 5
Reserves 137
167
179
Total Liabilities 487
53
CWIP 0
Investments 2
433
Total Assets 487

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2025
-29
-6
39
Net Cash Flow 4

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Mar 2025
Debtor Days 142
Inventory Days 265
Days Payable 160
Cash Conversion Cycle 247
Working Capital Days 202
ROCE %

Shareholding Pattern

Numbers in percentages

Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025
51.04% 51.04% 50.34% 50.15% 49.62% 49.31% 49.16% 49.17% 49.17% 48.93% 48.93% 48.93%
1.68% 1.68% 1.66% 1.65% 1.64% 1.60% 1.60% 1.60% 1.60% 1.59% 1.59% 1.59%
47.27% 47.27% 48.00% 48.20% 48.74% 49.08% 49.24% 49.24% 49.23% 49.47% 49.47% 49.47%
No. of Shareholders 3,6903,9014,1384,5214,6256,3136,8377,5077,5118,0188,1217,976

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Concalls